Tilray Medical supports scientific study on fibromyalgia

Tilray Medical announced a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series. The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia under the guidance of healthcare providers. The TOMAS study, consisting of patients with an average age of 52 years, examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study sheds light on the impact of cannabinoids on health outcomes, with a particular focus on pain, sleep, and quality of life. With medical cannabis guidance and supervision, the study demonstrated improvements in pain scores, sleep quality, and overall quality of life for fibromyalgia patients. Moreover, there was a notable reduction in co-medication, suggesting that cannabinoids may be an effective and cost-efficient treatment option for this population. The results of this study provide valuable insights for the medical and scientific community on the use of cannabinoids in managing chronic pain and improving the quality of life for patients with fibromyalgia.